Loading clinical trials...
Loading clinical trials...
Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners
It is known that teriflunomide, a treatment for relapsing forms of multiple sclerosis, can be found in low concentrations in semen. Because the drug has been associated with teratogenicity in laboratory animals, the question is raised as to whether the drug can be detected in female partners of sexually active males who are taking the drug to treat their multiple sclerosis.
A total of 10 couples were enrolled in the study. Females partners had undetectable or borderline levels of teriflunomide.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
Multiple Sclerosis Treatment Center at Griffin Hospital
Derby, Connecticut, United States
Start Date
October 1, 2015
Primary Completion Date
August 1, 2018
Completion Date
September 1, 2018
Last Updated
January 2, 2019
20
ACTUAL participants
Lead Sponsor
Griffin Hospital
NCT06276634
NCT07225504
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809192